Skip to main content
  1. Life
  2. Health & Fitness
  3. Healthcare

Libido-boosting female sex drug returns from limbo

See also

A pill that treats low sex drive in women is now back on track for review by the U.S. Food and Drug Administration (FDA), according to a statement by its maker Sprout Pharmaceuticals.

In 2010, the FDA rejected the drug, called flibanserin, saying the it failed to demonstrate safety and effectiveness in treating low sex drive—called hypoactive sexual desire disorder—in pre-menopausal women.

Hypoactive sexual desire disorder (HSDD) is the most commonly reported form of female sexual dysfunction. The condition affects about 10 percent of pre-menopausal women in the U.S., according to a study of flibanserin published in Journal of Sexual Medicine.

HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity. According to the company, the "absence of sexual fantasies and desire" causes distress or interpersonal difficulty.

The cause of HSDD is believed to involve various social, psychological and biological factors.

"In clinical trials, flibanserin has outperformed placebo with statistical significance and, importantly, women treated with flibanserin perceived their improvement to be clinically meaningful," said Cindy Whitehead, president and chief operating officer of Sprout Pharmaceuticals.

"It is true that flibanserin does not cause hypersexuality but by that definition, modest would be what we’re aiming for," said Whitehead.

Flibanserin is a non-hormonal drug similar to antidepressants such as Effexor (venlafaxine) and Wellbutrin (bupropion).

The company claims that flibanserin corrects an imbalance of brain chemicals: Dopamine and norepinephrine (both responsible for sexual excitement) and serotonin (responsible for sexual inhibition).

In studies, flibanserin was tested for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the distress women feel from HSDD.

In January, another drug for female sexual health achieved a milestone. Trimel Pharmaceuticals announced it completed enrollment for its ongoing study of Tefina—a nasal spray that contains a low dose of the hormone testosterone.

Tefina is being studied as a treatment for women with female orgasmic disorder (FOD). FOD is the persistent or recurrent delay in, or absence of, orgasm following normal sexual excitement.

As with the makers of flibanserin, the makers of Tefina say that an "absence of orgasm" causes personal distress or interpersonal difficulties.

-- Brett Grodeck



  • Dead babies found
    Seven dead babies were found in Utah resident Megan Huntsman's old home
    Shocking Discovery
  • Kendall Jenner
    Get the Coachella looks: Kendall Jenner’s nose ring, green hair and edgy nails
    Coachella Look
  • Dog's Easter basket
    How to fill your dog’s Easter basket with the perfect toys
    Easter Basket
  • Rabbit owners
    Bringing home the bunny: Important information for rabbit owners
    7 Photos
  • Haunted island
    The world’s most haunted island may soon be the most haunted luxury resort
    Haunted Resort
  • Sunken ferry
    Search continues for missing passengers after a ferry sinks off the South Korean coast
    Sunken Ferry

Related Videos:

  • FDA Warning to stop using Zi Xiu Tang Bee Pollen capsules
    <div class="video-info" data-id="517216545" data-param-name="playList" data-provider="5min" data-url=""></div>
  • Red hair and pale complexions on some Neanderthals say archaeogenetic researchers.
    <div class="video-info" data-id="518106227" data-param-name="playList" data-provider="5min" data-url=""></div>
  • People do online searches for health information more on Mondays than Saturdays.
    <div class="video-info" data-id="517755944" data-param-name="playList" data-provider="5min" data-url=""></div>

User login

Log in
Sign in with your email and password. Or reset your password.
Write for us
Interested in becoming an Examiner and sharing your experience and passion? We're always looking for quality writers. Find out more about and apply today!